Asahi Kasei Bioprocess and Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development
Asahi Kasei Bioprocess’ Massachusetts Training Center Expands 2024 Course Offerings for Career Development and Industry Training
Asahi Kasei offers Ceolus microcrystalline cellulose (MCC) with nitrite levels of 0.1 ?g/g (ppm) or less to contribute to reducing the risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements.
Asahi Kasei Offers Pharmaceutical Excipient Ceolus™ with Nitrite Concentration of 0.1 ppm or Less
Asahi Kasei develops novel membrane system to dehydrate organic solvents
AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project
NEW YORK, CHICAGO & SACRAMENTO, Calif.--(BUSINESS WIRE)--Asahi Kasei Bioprocess America, a subsidiary of diversified Japanese multinational company Asahi Kasei, and GeminiBio have entered into a strategic partnership to advance the application of inline buffer formulation (IBF) in the biopharmaceutical industry. Asahi Kasei Bioprocess, with decades of expertise in IBF and the developers of the award-winning MOTIV™ system, and GeminiBio, with industry leading bioprocess liquid manufacturing capabilities, are combining two high-efficiency solutions for buffer management to biopharmaceutical manufacturers in one package. This will result in fewer bottlenecks in manufacturing, streamlining the IBF process. The companies entered the agreement in March 2023 with the initial scope of the North American biopharmaceutical industry.
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1Â Study of Apraglutide in Japan
Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose
The Japanese conglomerate Asahi Kasei has put the finishing touches on a second plant to manufacture the pharma excipient microcrystalline cellulose (MCC) amid a growth in demand.